Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 10/20 | 0.39 |
| ▸ | UBA3 | Q8TBC4 | 9/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | GRK5 | P34947 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.37 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.34 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21283361 | 0.85 | CRHR1 (0.39) | NAE1UBA3CA2GRK5CSNK1A1 | |
| SCHEMBL21283385 | 0.84 | NAE1 (0.52) | NAE1UBA3CA2GRK5CSNK1A1 | |
| SCHEMBL21283366 | 0.81 | NAE1 (0.42) | NAE1UBA3CA2GRK5CSNK1A1 | |
| SCHEMBL21283396 | 0.81 | NAE1 (0.42) | NAE1UBA3CA2GRK5CSNK1A1 | |
| SCHEMBL21283358 | 0.77 | NAE1 (0.42) | NAE1UBA3CA2GRK5CSNK1A1 | |
| SCHEMBL192677 | 0.76 | NAE1 (0.57) | NAE1UBA3CA2GRK5CSNK1A1 | |
| SCHEMBL21283352 | 0.76 | NAE1 (0.53) | NAE1UBA3CA2GRK5CSNK1A1 | |
| SCHEMBL10236442 | 0.75 | NAE1 (0.47) | NAE1UBA3CA2GRK5CSNK1A1 | |
| SCHEMBL18872389 | 0.74 | NAE1 (0.58) | NAE1UBA3CA2GRK5CSNK1A1 | |
| SCHEMBL21283393 | 0.74 | AURKA (0.45) | NAE1UBA3CA2GRK5CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | ECE1, RNASE1, RCE1 | NAE1 41/4885UBA3 12/4885CA2 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.